Sevoflurane (SEV), a commonly used anesthetic agent for invasive surgery, is directly eliminated via exhaled breath and indirectly by metabolic conversion to inorganic fluoride and hexafluoroisopropanol (HFIP), which is also eliminated in the breath. We studied the postoperative elimination of SEV and HFIP of six patients that had undergone a variety of surgeries lasting between 2.5 to 8.5 hours using exhaled breath analysis. A classical three compartments pharmacokinetic model developed for the study of environmental contaminants was fitted to the breath data. We found that SEV kinetic behavior following surgery (for up to 6 days) is consistent across all subjects whereas the production and elimination of HFIP varies to some extent. We developed subject specific parameters for HFIP metabolism and interpreted the differences in the context of timing and dose of anesthesia, type of surgery, and specific host factors. We propose methods for assessing individual patient liver function using SEV as a probe molecule for assessing efficiency of liver metabolism to HFIP. This work is valuable not only for the clinical study of metabolism recovery, but potentially also for the study of the interaction of other manufactured and environmental compounds with human systems biology in controlled exposure and observational studies.
Introduction
Post-operative recovery from organ transplant is generally monitored with organ biopsy and/or assessment of specific biomarkers in blood. The recovery of liver function, in particular, can also be assessed by dynamic tests such as the plasma clearance of indocyanine green [1] , sulfobromophthaleinand galactose [2] or the monitoring in breath of metabolites of labeled compounds [3, 4] . However, all these procedures are invasive for requiring intravenous administration of xenobiotics.
We imagined that sevoflurane (SEV), an anesthetic routinely administered during surgery, may be used as a probe molecule to assess the recovery of liver function after a liver transplant. Liver function could be related to the production of a primary liver metabolite, hexafluoroisopropanol (HFIP), which like SEV can be monitored non-invasively in exhaled breath. In this work, we model the post-operative elimination of SEV and HFIP as a first step in developing a novel test for the liver function.
Anesthetics like SEV, desflurane, and isoflurane, as well as other common exogenous substrates (e.g. ethanol, caffeine) are all metabolized by cytochrome P450 2E1 (CYP2E1) [5, 6] . In humans, most (>90%) of CYP2E1 resides in the liver, with the remainder distributed in other organs including brain, kidney, and intestine. For modeling purposes, the extra-hepatic metabolism by CYP2E1 is considered negligible [7] , so we assigned any measurable production of HFIP as originating in the liver.
Our predictive mechanism is based on classical pharmacokinetic (PK) models for calculating adsorption, distribution, metabolism, and elimination of exogenous compounds [8, 9, 10, 11, 12, 13, 14, 15, 16] . We used literature values for SEV and HFIP pharmacokinetics [17] to build and calibrate an incremental model, which was tested against other literature data [18] and then applied to empirical data (SEV and HFIP measurements) and meta-data (duration of surgery, applied SEV concentration) from six patients who received invasive surgeries ranging from 2.5 to 8.5 hrs duration. A series of post-operative breath samples were collected and analyzed for SEV and HFIP and served to validate the original models and to interpret liver function. SEV (1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane, C 4 H 3 F 7 O) is currently one of the most used anesthetics due to its favourable pharmacokinetic properties (i.e. low blood-gas partition coefficient, low tissue solubility, fast metabolism and reduced cardio-depressant effect) [19, 20] . The low blood-gas solubility enables a rapid induction of anaesthesia and a rapid recovery at the end.
SEV is quickly eliminated via exhaled breath. Only a limited amount (1-5%) of the absorbed SEV undergoes a biotransformation to organic and inorganic metabolites, principally by CYP2E1 [6] . CYP2E1 catalyzed SEV oxidation produces equimolar amounts of inorganic fluoride and HFIP as the principal byproducts [21, 22, 23] . Once formed, HFIP is rapidly conjugated with glucuronic acid in the liver and excreted in urine as a glucuronide conjugate. The unconjugated fraction, representing less than 15% of total HFIP concentration [17] , is then eliminated via exhaled breath. Unconjugated HFIP and HFIPglucoronide appear in blood 5 minutes after the beginning of anaesthesia. The peak of HFIP concentration in plasma occurs 2-10 hours after the end of anaesthesia, with an average delay of 5.5 hours in patients receiving an average dose of 3.7 minimal alveolar concentration-hours (MAC-h) [24] .
The use of a safe probe molecule such as SEV has broader application than non-invasive clinical diagnosis of liver function; we envision that this approach may be implemented in other in vivo systems or for in vitro assessments of chemical toxicity using human cell-lines. This approach, wherein a specific molecule is used to develop a mode of action for organ involvement, lays the foundation for future work for exploring human systems biology in more general terms with respect to exposure science and risk assessment [25, 26] .
Materials and Methods

Empirical data from literature: A
The first data set comprised values from Kharasch et al. [17] . These subjects were nominally healthy nonsmokers with normal indexes for liver and renal function who underwent elective surgeries with a 3 hrs SEV anesthesia. Blood concentrations of SEV and HFIP were estimated from graphs and literature [17, 27] . They are reported in table 1 using the original units of μM in plasma and the expected concentrations (our estimate) in exhaled breath. For SEV, we used for conversion the accepted value 0.65 for blood/breath partition coefficient [27] and the near body temperature approximation of 24.2 liters/mole of an ideal gas. For HFIP, we first converted the total HFIP measurements into the expected free HFIP partition (see column 3) that is available for pulmonary elimination as discussed by Bordeaux et al. [27] . The blood/breath ratio for HFIP is not available in the literature, however, we estimated it to be 6.0 based on ratios of SEV/HFIP in plasma from Kharasch, compared to SEV/HFIP ratios in breath observed by us. The resultant calculated breath concentrations, expressed as parts per million by volume (ppmv) in air, are given in columns 5 and 6. These approximations serve only as scaling factors and so do not affect the shape of the graphs or the subsequent models. 
Empirical data from literature: B
A second set of blood data was estimated from graphs and discussions from Yasuda et al. [18] (table 2) .
These data do not include values for the metabolite HFIP and so are only useful for validating the uptake and elimination kinetics of SEV itself. These researchers administered 1% SEV gas for 30 minutes to seven healthy male volunteers (23 ± 3 yrs). Data are expressed as a ratio of end tidal exhalation and administered concentrations; for consistency with the previous dataset, we converted the data into ppmv in the last column of the table. 
Conceptual model
We developed a classical pharmacokinetic model based on the approximated breath data from Kharasch et al. [17] . The model, based on a previous work [13] , is developed for SEV using three empirical compartments: 1 st "central" compartment (blood), 2 nd compartment (HPT -highly perfused tissues), and 
Calculational model
Based on the concepts of linear kinetics and the diagram in figure 1, we write difference equations to calculate the concentrations in each of the compartments as an incremental function of time:
Subsequently, under the assumptions that breath concentrations are proportional (via blood/breath coefficients) to blood concentrations, we calculate:
where the C(t)'s denote concentrations, the subscripts identify the compartments and the compounds, C a represents the concentration of SEV in the anesthetic mixture and the K i 's and C i 's denote time constants as described in the previous section. The equations can be quickly implemented using a spreadsheet software. The blood/breath partition estimates (eq. 6 and 7) are linear functions and so any uncertainty is adjusted during the model fine-tuning procedure through the adjustment of a single scaling parameter.
Methods for estimating initial parameters
The incremental equations are quantified using reasonable estimates for rate parameters that are then adjusted to fit over the empirical data. Typically, the first step is to estimate the initial uptake rate parameter (Ca · Ko) using eq. 1 above. The initial conditions are that concentrations throughout the body are zero at time = 0 and we rearrange the equation setting C bloodSev (t) and C HPTSev (t) to be very close to zero, and solve for an estimate of the initial slope:
which can be empirically evaluated using the earliest (uptake) data points available. Given this initial estimate for the uptake parameter and an empirical estimate for the steady state concentration from data observation, we can estimate the initial half-life in the 1 st compartment using a re-arrangement of equation
1 from above and the understanding that the slope of the curve is zero:
and therefore:
This is further reduced with the assumption that [K 1 · C bloodSev (t)] ≈ [K 2 · C HPTSev (t)] at steady state conditions leaving the approximation:
where C bloodSev (t=ss) is the steady state concentration and (Ca · Ko) has been estimated in eq. 8.
Starting with these basic estimates from empirical data, we can construct the initial model and then empirically refine it with trial and error for the 2 nd and 3 rd compartments as well as the metabolite parameters. Initially, kinetic parameters are adjusted for the 2 nd compartment to fit the curvature of the elimination at 100 to 200 minutes; subsequently, the 3 rd compartment kinetic parameters are adjusted to fit the behavior past 200 minutes.
Chemical reagents
1,1,1,3,3,3-hexafluoro-2-propanol (puriss p.a. standard for GC grade > 99%) was purchased from Fluka, Sigma-Aldrich (Italy). SEV was from Abbott, Italy. Analytes were stored at 4 °C to minimize the risk of evaporation. Labelled toluene-D8 (purity 99.8 %) was purchased from ARMAR Chemicals (Switzerland).
Preparation of standards
A gaseous standard of SEV and HFIP was prepared by evaporating 5 μL of both liquids in a preevacuated glass flask (2 L) equipped with a septum and held at 40 °C. The corresponding concentrations were 480 ppmv for SEV and 610 ppmv for HFIP. Calibration curves for these compounds were obtained by transferring different volumes of the standard into sampling bags, and analysing the bag contents as they were breath samples.
A further gaseous standard of labelled toluene-D8 was prepared in another glass flask as described above, the corresponding concentration was 600 ppmv.
Breath sample collection
Disposable bags (approximate volume 5 L) were fabricated from a roll of Nalophan tube (polyethylene terephthalate film, thickness 20 µm) supplied from Kalle (Wiesbaden, Germany). One end of each paring was rolled and tightened by nylon cable ties, whereas the other end was wrapped and tightened around a PTFE tube connected to a stopcock, a one-way valve, and a mouthpiece. Each subject was asked to calmly fill a bag with multiple deep breaths.
Breath sample analysis
Stability tests were performed by filling Nalophan bags with standard mixtures. Results indicate that SEV concentrations were stable for 6 hours and decreased about 10% after 24 hours [28] . Sample analysis was started as soon as possible within two hours from sampling. Breath samples were collected at room temperature and then sampling bags were stabilized at 40 (±1) °C in a thermostated box for half an hour to prevent water condensation before loading a sample aliquot (250 mL) on the desorption tube. This aliquot was flowed through a drying tube filled with 9 g of anhydrous sodium sulphate for water removal, and a glass thermal desorption tube prepacked with 250 mg of Tenax GR (70% Tenax TA, 2,6-diphenylp-phenylene oxide and 30% graphitized carbon). During the sample transfer, the sampling bag and the drying tube were kept at 40 °C, whereas the desorption tube was at ambient temperature. Due to the high concentrations of SEV, only 50 mL of the samples collected in the first two days after surgery were 
Method evaluation
The GC/MS unit was calibrated by gaseous standards of SEV and HFIP at different concentrations that were prepared in pre-evacuated glass flasks, transferred into the sampling bags and analysed as normal samples. The system showed a good linearity (R 2 = 0.999) for both gases, in the ranges 0.1 -100 ppmv and 0.002 -0.6 ppmv for SEV and HFIP respectively. The stability of the response factor of the GC/MS unit was checked daily by the injection of a labelled standard (toluene-D8, 99.8% purity, Armar Chemicals). The limit of detection (LOD) was calculated by the software of the instrument as the concentration giving a signal with a signal-to-noise ratio of 3, and resulted 5 and 10 pptv for SEV and HFIP, respectively. The precision of the method was assessed by repeatability and reproducibility at a concentration level of 0.5 ppmv of both compounds and expressed as coefficient of variation. The coefficients of variation were calculated based on quintuplicate runs, analysed on the same day for repeatability and on different days for reproducibility. Within run and between run precision of the method resulted 3 and 10 %, respectively. The analytical recovery was estimated for SEV and HFIP by comparing the results of replicate analyses of a bag and the analyses of desorption tubes loaded with 1 μL of each liquid. This Nalophan bag (2.5 L) was prepared by injecting 10 μL of liquid SEV and HFIP in the flow of pure air during the filling, and its content was analyzed by loading 250 mL aliquots into desorption tubes. In these conditions, the recovery of the analytes was 93% and 95% respectively.
Human subjects
Time dependent post-operative breath samples were collected from six patients undergoing various surgeries. Research was conducted under approved Institutional Review protocols with informed consent. 
Breath measurement data
Post-operative breath samples were collected for up to 8-days. Table 4 provides exhaled breath concentrations by patient for the two compounds. We did not have the opportunity to collect samples during or immediately after surgery as these were all critically ill patients. Total dose values are estimates based on real time measurements of administered SEV by the surgery room monitor. 
Results
Initial model construction
The ppmv estimated data from Kharasch et al. was used to develop the SEV and HFIP incremental models using the approach presented in the methods section. The initial estimate for SEV uptake (Ca+Ko)
is 2482 ppm/min, the steady state concentration estimate in exhaled breath is 26,062 ppmv, and the initial elimination rate estimate (C1+K5) is 0.0952. Subsequently, higher compartments were empirically fitted and initial estimates were modified to account for approximations. Figure 2 (a) shows data overlaid onto the model. The two-compartment HFIP data were subsequently modeled by trial and error, and the data vs. model comparison is shown in figure 2 (b) . We see that both models represent the respective data sets well over a long time frame. There is a great variability in the HFIP measurements early in the postanesthesia period and so the model was fitted among these points and may not necessarily represent any specific individual. We have subsequently modeled the higher and lower data points separately to bracket the behavior in the first 500 minutes after the end of anesthesia (dashed curves, figure 2 (b) ). This was accomplished empirically by adjusting the K 5 and C 2 + C 3 parameters that govern HFIP kinetics at the individual level. We interpret this envelope to indicate the between-subject variability in HFIP metabolism, and possibly differences in phase-2 glucuronidation. The final results of the model parameters for the Kharasch data are given in Table 6 . Standard parameters for inter-individual variability for HFIP models and necessary adjustments from original Kharasch model in Table 5 . 
HFIP
Model application/validation: Yasuda data
To test the assumption that the SEV model (and by inference, the HFIP model) are both subject to linear kinetics, we apply the existing model from above to the completely independent data from Yasuda et al..
The only adjustment is for the different administered SEV concentration (10,000 ppmv) and shorter administration time (30 min). The model slightly under-predicts speed of uptake and speed of elimination (figure 3). We attribute this apparent higher pulmonary efficiency to the pre-selection of healthy young subjects (mean age 23 yrs) and the fact that they did not undergo invasive surgery. In contrast, the Kharasch's patients used to build the model all had invasive, albeit elective surgery and ranged from 23 to 68 yrs. in age. and levels are consistent. This is expected, as the Yasuda subjects were young, healthy volunteers (mean age 23 ± 3 yrs) without surgical intervention in contrast to the Kharasch patients that were appreciably older (mean age 44 ± 4 yrs) and undergoing invasive, albeit elective, surgery.
Model application: Pisa Surgical Data
Under the assumptions of linearity of classical PK, we used the fitted rate constants from the model development data (Kharasch) and applied the empirical model directly to the measurements (and time meta-data) made for six patients (tables 3 and 4). The only adjustment made was to calibrate the initial condition at t=0 for the SEV model for each individual as they all had different lengths of surgeries and different administered levels of anesthetic; the HFIP model parameters were left identical to the initial models shown in figure 2 (b) as the metabolism calculation is only dependent on SEV concentration.
In contrast to the excellent performance of the incremental PK model for SEV shown in figure 4 , the results for the empirical HFIP data are somewhat erratic. In figure 5 (a) we observe that four of the six patients (#'s 1, 2, 3, and 5) had the expected biologically damped elimination response, although the model tended to over-predict the production of HFIP in a range from 10% to 50%; Patients #4 and #6, however, exhibited an anomalous HFIP response. Rather than the expected damped exponential elimination, they both increased over time for 24 and 48 hours, respectively. Figure 5 (b) shows the empirical measurements, the expected PK behavior, and an empirical sketch that required a polynomial to approximate the actual shape. The depression of response with respect to the model based on Kharasch data for subjects 1, 2, 3, and 5
( figure 5 (a) ) can be interpreted as lower efficiency of CYP2E1 function in the liver. This is not surprising as the model is based on moderately healthy patients undergoing elective surgery (Kharasch 1991) , whereas the subjects of this study were older and less healthy having very invasive life-saving surgeries.
For this reason, we recalculated the HFIP response for these initial four subjects by decreasing the rate of HFIP formation in 5% steps below that of the mean value from the Kharasch based model. We found that this gives a better model approximation, but still did not fully explain the shape of the curve. We then further adjusted the loss parameter of HFIP from the blood; this is a composite of the efficiency of ventilation and the relative amount of removal via glucuronidation achieving a predictive model that now fits empirical measurements.
For subjects 4 and 6, the interpretation is more difficult; there appears to be a time delay in production of HFIP in addition to rate differences (recall figure 5 (b) ). The adjusted parameters for all subjects are The apparent delay (and reduction) in HFIP production is significant in a number of ways. First, it may be a non-invasive assessment of overall liver function due to surgical trauma or possibly due to needed repair functions that could overwhelm or saturate the CYP2E1 metabolism of SEV. Second, it could be used eventually as an indicator of return to function after transplantation and reperfusion. The models could easily be calibrated (as they were for subjects 4 and 6) to assess such parameters. From an environmental exposure standpoint, SEV could conceivably be used as a probe molecule at low levels to assess population based liver function in various urban, suburban, and rural environments.
Discussion
The implementation of a simple iterative PK model shown that the kinetics and metabolism of a tracer compound (SEV) can be explored in a general manner from literature values. The model was applied to a new set of observations from different patients under the assumptions of linear kinetics to predict bloodand breath-borne SEV concentrations. Subsequently, we developed an incremental model that calculates the production of HFIP, the primary metabolite of SEV, under the assumption of normal (nominally healthy) metabolism. We proposed that monitoring HFIP simultaneously with SEV tracer compound is a direct link to CYP2E1 metabolism, and as such, deviations from expected HFIP production is a marker for liver function efficiency. 
